Cingulate Inc. (CING) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.39K; Additional Paid in CapitalUSD $171.02M; Retained Earnings (Accumulated Deficit)USD $-147.56M; Stockholders' Equity Attributable to ParentUSD $23.47M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.19K; Additional Paid in CapitalUSD $160.55M; Retained Earnings (Accumulated Deficit)USD $-141.69M; Stockholders' Equity Attributable to ParentUSD $18.86M.
- 2025-12-31: Common Stock, Value, IssuedUSD $725.00; Additional Paid in CapitalUSD $134.88M; Retained Earnings (Accumulated Deficit)USD $-132.38M; Stockholders' Equity Attributable to ParentUSD $2.51M.
- 2025-09-30: Common Stock, Value, IssuedUSD $596.00; Additional Paid in CapitalUSD $129.58M; Retained Earnings (Accumulated Deficit)USD $-126.10M; Stockholders' Equity Attributable to ParentUSD $3.47M.
Cingulate Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.39K | $171.02M | $-147.56M | $23.47M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.19K | $160.55M | $-141.69M | $18.86M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $725.00 | $134.88M | $-132.38M | $2.51M | (m) | 12 month · $1.43M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $596.00 | $129.58M | $-126.10M | $3.47M | (m) | 3 month · $592.82K | (m) | (m) | (m) | (m) |
| 2025-06-30 | $488.00 | $122.59M | $-117.08M | $5.51M | (m) | 3 month · $90.72K | (m) | (m) | (m) | (m) |
| 2025-03-31 | $382.00 | $118.22M | $-112.29M | $5.93M | (m) | 3 month · $357.65K | (m) | (m) | (m) | (m) |
| 2024-12-31 | $340.00 | $117.38M | $-109.93M | $7.46M | 12 month · $586.51K | 12 month · $995.47K | 12 month · $2.73M | (m) | (m) | (m) |
| 2024-09-30 | $305.00 | $114.39M | $-102.36M | $12.04M | (m) | 3 month · $393.77K | (m) | (m) | (m) | (m) |
| 2024-06-30 | $78.00 | $102.21M | $-99.13M | $3.08M | (m) | 3 month · $254.33K | (m) | (m) | (m) | (m) |
| 2024-03-31 | $502.00 | $99.13M | $-95.92M | $3.22M | 3 month · $586.51K | 3 month · $164.57K | 3 month · $2.73M | (m) | (m) | (m) |
| 2023-12-31 | $10.00 | $86.07M | $-92.94M | $-6.87M | 12 month · $1.86M | 12 month · $812.67K | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.74K | $85.91M | $-86.01M | $-96.33K | 3 month · $1.86M 9 month · $1.86M | 3 month · $236.25K | 3 month · $3.95M | (m) | (m) | (m) |
| 2023-06-30 | $1.21K | $73.93M | $-80.03M | $-6.10M | (m) | 3 month · $217.38K | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.13K | $73.49M | $-73.41M | $81.61K | (m) | 3 month · $204.48K | (m) | (m) | (m) | (m) |
| 2022-12-31 | $61.00 | $73.29M | $-69.41M | $3.88M | (m) | 12 month · $800.80K | (m) | (m) | 12 month · $85.92K | (m) |
| 2022-09-30 | $1.13K | $73.17M | $-64.80M | $8.37M | (m) | 3 month · $205.66K | (m) | (m) | (m) | (m) |
| 2022-06-30 | $1.13K | $72.96M | $-60.78M | $12.18M | (m) | 3 month · $207.19K | (m) | $-3.25K | (m) | (m) |
| 2022-03-31 | $1.13K | $72.76M | $-56.74M | $16.02M | (m) | 3 month · $181.52K | (m) | $-2.78K | (m) | (m) |
| 2021-12-31 | $1.13K | $72.57M | $-51.73M | $20.84M | (m) | 12 month · $43.84K | (m) | $165.00 | (m) | 12 month · $12.74M |
| 2021-09-30 | (m) | (m) | (m) | $3.08M | (m) | (m) | (m) | (m) | (m) | 3 month · $12.74M |
| 2021-06-30 | (m) | (m) | (m) | $1.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $1.34M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $-31.02M | $1.29M | (m) | (m) | (m) | $165.00 | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $615.88K | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |